Cite
HARVARD Citation
Dimopoulos, M. et al. (n.d.). Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet oncology. 18 (10), pp. 1327-1337. [Online].